Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBITDA (2023 - 2025)

Kura Oncology (KURA) has disclosed EBITDA for 3 consecutive years, with -$80.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 311.78% to -$80.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$291.4 million, a 69.47% decrease, with the full-year FY2025 number at -$278.4 million, down 61.91% from a year prior.
  • EBITDA was -$80.6 million for Q4 2025 at Kura Oncology, down from -$80.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$19.6 million in Q4 2024 to a low of -$80.6 million in Q4 2025.
  • A 3-year average of -$50.8 million and a median of -$49.8 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 51.71% in 2024, then plummeted 311.78% in 2025.
  • Kura Oncology's EBITDA stood at -$40.5 million in 2023, then skyrocketed by 51.71% to -$19.6 million in 2024, then crashed by 311.78% to -$80.6 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's EBITDA are -$80.6 million (Q4 2025), -$80.0 million (Q3 2025), and -$66.1 million (Q2 2025).